| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Tetrahydrocortisone acetate itself does not possess a pharmacologically active target. As a metabolite of cortisone resulting from complete saturation of ring A by 5β-reductase, this compound lacks the Δ⁴-3-keto structure necessary for glucocorticoid activity and therefore cannot effectively bind to the glucocorticoid受体. Its biological significance lies in serving as a metabolic marker: in clinical research, the urinary ratio of tetrahydrocortisone (THE) to tetrahydrocortisol (THF) (THE/THF) is widely used to assess the activity of 11β-hydroxysteroid dehydrogenase (11β-HSD).
|
|---|---|
| ln Vitro |
Tetrahydrocortisone acetate itself does not possess directly measurable in vitro pharmacological activity. As a terminal inactivated metabolite of cortisone and hydrocortisone, this compound does not exhibit anti-inflammatory, immunosuppressive, or glucocorticoid effects. In in vitro studies, it is primarily used as a reference standard in mass spectrometry for calibrating and quantifying tetrahydrocortisone levels in biological matrices (such as plasma and urine), rather than as an active compound for pharmacodynamic evaluation.
|
| ln Vivo |
Tetrahydrocortisone acetate does not possess direct in vivo pharmacodynamic activity. In vivo, it is one of the major terminal inactive products generated from the hepatic metabolism of cortisone and cortisone acetate. Its in vivo levels reflect the metabolic status of upstream corticosteroids: research has shown that in pediatric patients with congenital adrenal hyperplasia (CAH) receiving cortisone acetate therapy, the urinary THE/THF ratio is significantly elevated during periods of poor disease control (6.56 ± 2.51 vs 3.73 ± 0.96), indicating that THE (tetrahydrocortisone) serves as an important biomarker for glucocorticoid metabolic clearance rather than a therapeutically active substance.
|
| Enzyme Assay |
Tetrahydrocortisone acetate can be used as a substrate or product to study the activity of 11β-hydroxysteroid dehydrogenase (11β-HSD). A typical non-cellular assay protocol is as follows: Pre-incubate recombinantly expressed purified 11β-HSD enzyme (type I or II) with cofactor (NADP⁺ for dehydrogenation or NADPH for reduction) in reaction buffer at 37°C for 5 minutes. Subsequently, add Tetrahydrocortisone acetate or tetrahydrocortisone as substrate (final concentration 0.1-100 μM) to initiate the reaction in a total volume of 200 μL. After incubation at 37°C for 30-60 minutes, terminate the reaction by adding ice-cold acetonitrile and centrifuge to remove protein. Analyze the supernatant using LC-MS/MS to quantify substrate consumption and product formation, thereby calculating enzyme kinetic parameters (Km, Vmax) or inhibitory activity.
|
| Cell Assay |
The application of Tetrahydrocortisone acetate in cellular experiments is primarily focused on metabolic studies rather than activity assays. A typical protocol is as follows: Seed human hepatoma cells (e.g., HepG2) at a density of 5×10⁵ cells per well in 6-well plates and culture at 37°C in 5% CO₂ for 24 hours until adherence. Prepare serial concentrations (0.1-50 μM) of Tetrahydrocortisone acetate in serum-free medium (prepare stock solution in DMSO, then dilute with culture medium to working concentration) and add to cells for 6-24 hours of treatment. Collect cell culture supernatant and cell lysate, purify via solid-phase extraction (SPE), and detect the formation of glucocorticoid metabolites inside and outside cells using LC-MS/MS. MTT or CCK-8 assays can be used to evaluate the impact of this compound on cell viability.
|
| Animal Protocol |
The primary application of Tetrahydrocortisone acetate in in vivo animal experiments is as a metabolite standard in pharmacokinetic (PK) studies. A typical experimental protocol is as follows: Use male SD rats (body weight 180-220 g), administer cortisone or cortisone acetate via tail vein injection (1-5 mg/kg) or oral gavage (5-20 mg/kg), then collect blood samples into heparinized tubes at different time points (5, 15, 30, 60, 120, 240, 480 minutes), along with 24-hour urine samples. After centrifugation of blood samples to separate plasma, add internal standard for protein precipitation and liquid-liquid extraction; urine samples are directly analyzed after appropriate dilution. Quantify metabolites including tetrahydrocortisone using validated LC-MS/MS methods, plot plasma concentration-time curves of the parent drug and its metabolites, and calculate pharmacokinetic parameters.
|
| ADME/Pharmacokinetics |
Tetrahydrocortisone acetate itself is not a dosage form, but rather an in vivo metabolite of cortisone/hydrocortisone. In vivo, after oral administration of cortisone acetate, it undergoes hepatic first-pass metabolism, being converted to active hydrocortisone by the reductase component of 11β-HSD, and subsequently to tetrahydrocortisone via 5β-reductase (AKR1D1). The calculated LogP value of this compound is approximately 2.43, indicating certain lipophilic properties. Tetrahydrocortisone is further conjugated with glucuronic acid to form tetrahydrocortisone 3-glucuronide, ultimately excreted in urine via the kidneys. In clinical studies, the urinary excretion of tetrahydrocortisone is used as a biomarker to assess the metabolic clearance rate of glucocorticoids.
|
| Toxicity/Toxicokinetics |
As an endogenous inactivated metabolite of cortisone and hydrocortisone, this compound is present in human urine under normal physiological conditions and is generally not considered to have significant toxicity. Due to the complete absence of the Δ⁴-3-keto structure required for glucocorticoid activity, this compound cannot activate the glucocorticoid receptor and therefore does not cause the typical adverse reactions associated with glucocorticoid excess (such as immunosuppression, hyperglycemia, osteoporosis, etc.). In laboratory use, this compound is for research use only and should be handled following standard operating procedures (SOPs), avoiding inhalation, ingestion, or skin contact.
|
| References |
[1]. A novel synthesis of tetrahydrocortisone 3-glucuronide. Journal of Carbohydrate Chemistry. Volume 41, 2022 - Issue 1.
|
| Molecular Formula |
C23H34O6
|
|---|---|
| Molecular Weight |
406.51246
|
| Exact Mass |
406.236
|
| CAS # |
17736-20-8
|
| Related CAS # |
Tetrahydrocortisone;53-05-4
|
| PubChem CID |
223685
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.228g/cm3
|
| Boiling Point |
557ºC at 760mmHg
|
| Flash Point |
187.4ºC
|
| Vapour Pressure |
9.97E-15mmHg at 25°C
|
| Index of Refraction |
1.549
|
| LogP |
2.432
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(OCC([C@]1(CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](CC[C@]4(C)[C@H]3C(C[C@]12C)=O)O)O)=O)=O
|
| InChi Key |
MULICLCRGFYQJF-LLTWYMBTSA-N
|
| InChi Code |
InChI=1S/C23H34O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h14-17,20,25,28H,4-12H2,1-3H3/t14-,15-,16+,17+,20-,21+,22+,23+/m1/s1
|
| Chemical Name |
[2-[(3R,5R,8S,9S,10S,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
|
| Synonyms |
3alpha,17,21-Trihydroxy-5beta-pregnane-11,20-dione 21-acetate; [2-[(3R,5R,8S,9S,10S,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate; TETRAHYDROCORTISONE ACETATE; MLS002638216;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4600 mL | 12.2998 mL | 24.5996 mL | |
| 5 mM | 0.4920 mL | 2.4600 mL | 4.9199 mL | |
| 10 mM | 0.2460 mL | 1.2300 mL | 2.4600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
